BCAB — Bioatla Income Statement
0.000.00%
Last trade - 00:00
- $101.24m
- -$10.23m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 5.2 | 0.429 | 0.25 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 33.5 | 33.4 | 96 | 108 | 130 |
Operating Profit | -28.3 | -33 | -95.8 | -108 | -130 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -29.9 | -35.9 | -95.4 | -106 | -123 |
Net Income After Taxes | -29.9 | -35.9 | -95.4 | -106 | -123 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -29.8 | -35.9 | -95.4 | -106 | -123 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -28.7 | -35.9 | -95.4 | -106 | -123 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.895 | -1.03 | -2.78 | -2.74 | -2.58 |
Dividends per Share |